Related Experiment Videos
Interferon as a treatment for uveitis associated with multiple sclerosis.
M D Becker1, A Heiligenhaus, T Hudde
1FEBO, Interdisciplinary Uveitis Center, University of Heidelberg, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. matthias.becker@uveitiscenter.de
The British Journal of Ophthalmology
|September 20, 2005
Summary
Type I interferons (IFN) show promise in treating multiple sclerosis (MS)-associated uveitis. This pilot study found IFN treatment improved visual acuity and reduced intraocular inflammation and macula edema in MS patients with uveitis.
Area of Science:
- Ophthalmology
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) can affect the eyes, causing intermediate uveitis in addition to optic neuritis.
- Ophthalmological and neurological symptoms in MS may share similar underlying pathogenic mechanisms.
Purpose of the Study:
- To evaluate the efficacy of type I interferons (IFN) for treating MS-associated uveitis.
- To assess the impact of IFN on visual acuity, intraocular inflammation, and cystoid macular edema (CMO).
Main Methods:
- A retrospective observational case series of 13 MS patients with uveitis treated with interferon beta-1a.
- Data collected included visual acuity, aqueous and vitreous humor cell counts, and presence of CMO.
Main Results:
- Interferon beta-1a treatment improved visual acuity in 17 out of 24 affected eyes.
- Significant reductions in aqueous and vitreous humor cell counts were observed.
- Cystoid macular edema (CMO) resolved in nine eyes during or after IFN treatment.
Conclusions:
- Type I interferons demonstrate beneficial effects for MS-associated uveitis.
- IFN treatment positively impacts visual acuity, reduces intraocular inflammation, and resolves CMO in MS patients.